Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) EBITDA (2016 - 2025)

Historic EBITDA for Niagen Bioscience (NAGE) over the last 17 years, with Q3 2025 value amounting to $4.2 million.

  • Niagen Bioscience's EBITDA rose 16441.95% to $4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.3 million, marking a year-over-year increase of 421856.82%. This contributed to the annual value of $7.7 million for FY2024, which is 23798.89% up from last year.
  • Per Niagen Bioscience's latest filing, its EBITDA stood at $4.2 million for Q3 2025, which was up 16441.95% from $3.2 million recorded in Q2 2025.
  • Niagen Bioscience's 5-year EBITDA high stood at $7.1 million for Q4 2024, and its period low was -$8.8 million during Q3 2021.
  • In the last 5 years, Niagen Bioscience's EBITDA had a median value of -$1.4 million in 2022 and averaged -$1.7 million.
  • Its EBITDA has fluctuated over the past 5 years, first plummeted by 11070.07% in 2021, then soared by 433273.81% in 2024.
  • Quarter analysis of 5 years shows Niagen Bioscience's EBITDA stood at -$5.3 million in 2021, then skyrocketed by 72.84% to -$1.4 million in 2022, then skyrocketed by 88.37% to -$168000.0 in 2023, then soared by 4332.74% to $7.1 million in 2024, then tumbled by 40.43% to $4.2 million in 2025.
  • Its EBITDA stands at $4.2 million for Q3 2025, versus $3.2 million for Q2 2025 and $4.8 million for Q1 2025.